Cayuga Biotech Raises $5M Seed Funding

Cayuga Biotech, a clinical-stage biopharmaceutical company, has secured $5,000,000 in new investment from a recent funding round.

The company focuses on developing novel therapies aimed at addressing life-threatening hemorrhage by harnessing the body’s innate ability to stop bleeding.

This significant capital infusion marks a pivotal moment for Cayuga Biotech as it continues to advance its innovative pipeline.

The company's therapeutic pipeline includes CAY001 (polyP-SNP complex), currently in clinical-stage development for acute major hemorrhage.

Additionally, Cayuga Biotech is progressing CAY002, a discovery-stage program targeting inherited bleeding disorders, alongside a portfolio of earlier-stage programs focused on the broader healing continuum.

These programs represent the company's commitment to addressing critical unmet medical needs.

The $5,000,000 in funding will be strategically deployed to accelerate the development of Cayuga Biotech’s lead clinical candidate, CAY001, and to further expand its discovery and early-stage programs.

This investment underscores investor confidence in the company's scientific platform and its potential to deliver transformative treatments.

The capital will also support the expansion of its research and development capabilities, driving its mission forward.

This funding round is vital for Cayuga Biotech's continued growth, enabling the company to push its therapeutic candidates closer to patients.

The company looks forward to leveraging this investment to achieve key milestones and advance its mission of bringing innovative solutions to individuals facing life-threatening bleeding conditions, ultimately aiming to improve patient outcomes worldwide.